Docoh
Loading...

PODD Insulet

News

Pro users get this 30m faster
Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use
30 Sep 21
Biotech, News, Health Care, General
Insulet Corporation Announces Co.'s Omnipod 5 Pivotal Study Extension Data Shows Significant Improvements In Glycemic Control With One Year Of Use
30 Sep 21
Biotech, News, FDA, General
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has presented positive pivotal trial extension phase results for
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
9 Sep 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
8 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7)
Looking into Insulet's Return on Capital Employed
23 Aug 21
Earnings
After pulling data from Benzinga Pro it seems like during Q2, Insulet (NASDAQ:PODD) earned $26.30 million, a 61.35% increase from the preceding quarter. Insulet also posted a total of $263.20 million in sales, a 4.32% increase since Q1.
FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps
16 Aug 21
Biotech, News, Health Care, FDA, General
Insulet Announces FDA Clearance of Lyumjev Rapid-Acting Insulin for Use with Omnipod® Products in the United States
16 Aug 21
News, FDA
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced FDA clearance for use of Eli Lilly and Company’s
SVB Leerink Maintains Outperform on Insulet, Lowers Price Target to $300
6 Aug 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Danielle Antalffy maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $325 to $300.
Insulet Q2 GAAP EPS $(0.37), Adj. EPS $0.23, Sales $263.20M Beat $259.19M Estimate
5 Aug 21
Earnings, News
Insulet (NASDAQ: PODD) reported quarterly losses of $(0.37) per share. This is a 268.18 percent decrease over earnings of $0.22 per share from the same period last year.
Earnings Scheduled For August 5, 2021
5 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

Press releases

Pro users get this 30m faster
Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford
18 Oct 21
Press Releases
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Luciana Borio, M.D., has been appointed to
Insulet's Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of Use
30 Sep 21
Press Releases
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has presented positive pivotal trial extension phase results
Insulet to Announce Third Quarter 2021 Financial Results on November 4, 2021
29 Sep 21
Press Releases
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the
Insulet to Present at Upcoming Investor Conferences
26 Aug 21
Press Releases
Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming virtual
Insulet Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States
16 Aug 21
Press Releases
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced FDA clearance for use of Eli Lilly and Company's
Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year
5 Aug 21
Press Releases
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended
Insulet to Present at Upcoming Investor Conferences
26 Jul 21
Press Releases
Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at two upcoming virtual investor